Introduction
Titanium dioxide remains an approved excipient in pharmaceutical products across every major market, including the European Union, where regulators have reaffirmed its use after years of review. This single fact often gets lost in conversations that buyers have absorbed from the food industry, where titanium dioxide was banned as an additive in 2022. The pharmaceutical use case is governed by a separate framework, and the two should not be confused when a procurement team is evaluating a coating system.
The confusion has a real cost. A formulator who assumes titanium dioxide is on its way out of pharmaceutical formulations may begin reformulation work that is not currently required, or may select a coating system based on an alternative opacifier without understanding the trade-offs that come with it. At the same time, the regulatory conversation around titanium dioxide has not ended, and a buyer who assumes nothing will ever change is equally unprepared.
For a coating polymer supplier, this means the conversation with a formulator needs to cover both the current regulatory position and the practical considerations around alternatives, without overstating either the risk or the readiness of substitutes. At Vikram Thermo (India) Ltd., our DRCOAT® and DRUGCOAT® ranges are formulated for both titanium dioxide containing and titanium dioxide free systems, and this article sets out what buyers need to know to make that choice with current information.
What TiO2 Does in a Pharmaceutical Coating
Titanium dioxide functions as an opacifier and white pigment in tablet and capsule coatings. Its high refractive index scatters light effectively, which gives a coating its hiding power over a mottled or coloured tablet core and gives the finished product the uniform white appearance that patients and prescribers associate with consistency.
Beyond appearance, opacity has a functional role. A coating with sufficient hiding power protects light sensitive active ingredients from photodegradation during storage and shelf life. For formulations where the active ingredient degrades under light exposure, the opacifying capacity of the coating is not a cosmetic detail. It is part of the stability profile of the product.
Titanium dioxide also contributes to batch to batch visual consistency. Two batches coated with the same formulation should look identical on a pharmacy shelf, and an opacifier with stable particle size and refractive properties supports that consistency across production runs.
Why It Matters
The regulatory history of titanium dioxide has created uncertainty that does not match its current approval status. The European Union banned titanium dioxide as a food additive in 2022, a decision based on genotoxicity concerns raised by the European Food Safety Authority. That ban applies to food products and does not extend to pharmaceuticals, but it triggered a separate review of titanium dioxide's use in medicinal products.
That review has now concluded. In August 2025, the European Commission published a Staff Working Document confirming that titanium dioxide remains approved as a colorant in medicinal products. This followed an April 2024 review by the European Medicines Agency, which found that titanium dioxide is essential for the safety, quality and efficacy of a large share of the medicines that contain it. The Agency identified no viable alternatives across the roughly 91,000 human medicinal products and 1,600 veterinary products that currently use titanium dioxide, and estimated that reformulating that scale of the pharmaceutical portfolio would take more than 12 years once regulatory post-approval processes are accounted for.
Outside the EU, the position has remained stable. In the United States, titanium dioxide continues to be authorised as a color additive exempt from certification, and no other major regulatory jurisdiction has followed the EU's food additive ban as it applies to pharmaceuticals.
For a buyer, the practical takeaway is that titanium dioxide is not currently a compliance risk in the way that nitrosamines or certain solvent residues are. It is, however, a topic that procurement and regulatory teams should expect to be asked about, by auditors, by customers in markets sensitive to the food additive ban and by internal stakeholders who have seen the headlines without the regulatory context behind them.
The Regulatory Position in Detail
Two separate regulatory tracks need to be kept distinct.
The food additive track. Titanium dioxide, designated E171, was withdrawn as an authorised food additive in the European Union under Commission Regulation (EU) 2022/63, effective from August 2022. This decision applied to food and dietary supplements and was driven by genotoxicity concerns identified in an EFSA safety assessment.
The pharmaceutical excipient track. The European Commission separately asked the European Medicines Agency to assess what removing titanium dioxide from medicinal products would mean. The EMA's review concluded in 2024, and the Commission's August 2025 Staff Working Document confirmed that titanium dioxide remains permitted under Regulation (EU) 2022/63 for use in medicines, on the basis that no viable alternative currently meets the functional and safety requirements across the full range of affected products.
These two tracks have run on different timelines and reached different conclusions, and a buyer who only saw coverage of the food additive ban may not be aware that the pharmaceutical question has since been resolved in favour of continued use, at least for the present regulatory cycle.
Alternatives to TiO2 and Their Trade-Offs
Even with titanium dioxide's continued approval, some formulators are exploring alternatives, whether for specific markets with heightened sensitivity, for new product development where a titanium dioxide free claim has commercial value, or simply to build familiarity with substitutes ahead of any future regulatory change.
Calcium carbonate is the most commonly cited alternative and is the only other white drug colorant currently approved in the EU. Particle engineered grades of calcium carbonate can achieve opacity and process efficiency that approach titanium dioxide performance, with tablet properties such as friability and hardness reported as comparable in coated tablets.
The trade-offs are real. Achieving opacity close to titanium dioxide typically requires a thicker coating, which means a higher coating weight gain and a longer process time. Even with a thicker film, the resulting opacity has in some studies been insufficient to protect photolabile active ingredients to the same degree as titanium dioxide. Calcium carbonate also has buffering properties and can shift the local pH of the dosage form, which raises compatibility considerations for acidic active ingredients such as salicylic acid or certain antibiotics.
Other inorganic opacifiers including magnesium carbonate, calcium sulfate, talc and aluminium silicates have also been studied, but none has been identified as a complete substitute that addresses both the functional performance and the long term regulatory profile that titanium dioxide currently offers.
The practical conclusion is that alternatives exist and can work for specific formulations, but none currently functions as a direct drop-in replacement across the full range of dosage forms and active ingredients where titanium dioxide is used today.
How This Affects Coating System Selection
For a formulator working with DRCOAT® ready-to-use coating systems or building a custom formulation with DRUGCOAT® polymers, titanium dioxide content is one specification among several, and it should be evaluated alongside the rest of the formulation rather than in isolation.
If the active ingredient is photolabile, the opacifying performance of the coating system needs to meet the stability requirements demonstrated in development, and any change to the opacifier should be evaluated against the same photostability data that supported the original formulation.
If the formulation includes a titanium dioxide free coating system, the buyer should ask what opacifier is used in its place, what coating weight gain is required to achieve the target appearance, and whether any compatibility studies have been completed for the specific active ingredient.
If the current formulation uses titanium dioxide and there is no regulatory or commercial driver to change it, the most defensible position is often to continue with the current formulation while staying informed about the regulatory position, rather than undertaking a reformulation in response to a ban that does not currently apply to the product.
Applications by Dosage Form
Common Challenges
Conflating the food additive ban with pharmaceutical status. This is the most common source of confusion among buyers, and it leads to questions and sometimes reformulation decisions based on a ban that does not apply to the product in question.
Underestimating the coating weight gain impact of alternatives. A formulator who switches to an alternative opacifier without adjusting the coating process parameters may find the target appearance is not achieved at the original coating weight, requiring rework.
Assuming all titanium dioxide free systems are equivalent. Different alternative opacifiers carry different compatibility profiles, particularly around pH sensitive active ingredients, and a titanium dioxide free claim does not by itself indicate which alternative is used or whether it has been validated for a specific formulation.
Treating the regulatory position as permanent. The current approval reflects the present regulatory cycle. Buyers in regulated markets should keep a watching brief on this topic without acting prematurely on it.
Formulation Insights
The titanium dioxide conversation illustrates a broader point about excipient selection. A regulatory question that dominates industry discussion for several years can resolve in favour of the status quo, and a formulation strategy built around an anticipated ban that does not materialise carries its own costs in reformulation effort and validation work.
At the same time, having a titanium dioxide free option available, validated and ready, costs little relative to the disruption of needing one quickly if the regulatory position does change in a future review cycle. Our approach is to support both paths: continued supply of titanium dioxide containing DRCOAT® and DRUGCOAT® systems for formulations where no change is needed, and titanium dioxide free formulations for buyers who want that option in place now.
FAQ
1. Is titanium dioxide banned in pharmaceutical products?
No. Titanium dioxide is banned as a food additive in the European Union since 2022, but this does not apply to pharmaceuticals. The European Commission confirmed in August 2025 that titanium dioxide remains approved for use in medicinal products.
2. Why was titanium dioxide reviewed for pharmaceutical use if the food ban does not apply?
The European Commission asked the European Medicines Agency to assess the question separately, given the genotoxicity concerns that drove the food additive ban. The Agency's review concluded that titanium dioxide is essential and that no viable alternative currently exists across the full range of affected medicines.
3. What is the main alternative to titanium dioxide in coatings?
Calcium carbonate, particularly particle engineered grades, is the most studied alternative and the only other white drug colorant approved in the EU. It typically requires a thicker coating to approach the opacity of titanium dioxide.
4. Should we reformulate away from titanium dioxide now?
Not on the basis of current regulation, unless a specific market or customer requirement drives it. The pharmaceutical approval was reaffirmed in 2025. A titanium dioxide free option can still be developed in parallel as a contingency.
5. Do DRCOAT® and DRUGCOAT® systems support titanium dioxide free formulations?
Yes. Both ranges can be formulated with or without titanium dioxide depending on the requirements of the dosage form and the active ingredient.
Conclusion
The titanium dioxide question has moved from an open regulatory uncertainty to a resolved position, at least for the current cycle, and buyers who continue to treat it as an unresolved risk are working from outdated information. The more useful question for a formulation team is not whether titanium dioxide will be banned, but whether the current coating system, with or without titanium dioxide, meets the opacity and stability requirements of the specific product.
Our DRCOAT® and DRUGCOAT® ranges are formulated to support both titanium dioxide containing and titanium dioxide free systems, backed by EXCiPACT GMP certification, US DMF registration and WHO cGMP compliance across the range.
Evaluating TiO2 in Your Coating System? Talk to Us.
Tell us whether your current formulation uses titanium dioxide and what your regulatory or commercial drivers are for considering a change. We will share the formulation options and stability considerations relevant to your dosage form.
Write to us at contact@vikramthermo.com
%201.jpg)
Introduction
Titanium dioxide remains an approved excipient in pharmaceutical products across every major market, including the European Union, where regulators have reaffirmed its use after years of review. This single fact often gets lost in conversations that buyers have absorbed from the food industry, where titanium dioxide was banned as an additive in 2022. The pharmaceutical use case is governed by a separate framework, and the two should not be confused when a procurement team is evaluating a coating system.
The confusion has a real cost. A formulator who assumes titanium dioxide is on its way out of pharmaceutical formulations may begin reformulation work that is not currently required, or may select a coating system based on an alternative opacifier without understanding the trade-offs that come with it. At the same time, the regulatory conversation around titanium dioxide has not ended, and a buyer who assumes nothing will ever change is equally unprepared.
For a coating polymer supplier, this means the conversation with a formulator needs to cover both the current regulatory position and the practical considerations around alternatives, without overstating either the risk or the readiness of substitutes. At Vikram Thermo (India) Ltd., our DRCOAT® and DRUGCOAT® ranges are formulated for both titanium dioxide containing and titanium dioxide free systems, and this article sets out what buyers need to know to make that choice with current information.
What TiO2 Does in a Pharmaceutical Coating
Titanium dioxide functions as an opacifier and white pigment in tablet and capsule coatings. Its high refractive index scatters light effectively, which gives a coating its hiding power over a mottled or coloured tablet core and gives the finished product the uniform white appearance that patients and prescribers associate with consistency.
Beyond appearance, opacity has a functional role. A coating with sufficient hiding power protects light sensitive active ingredients from photodegradation during storage and shelf life. For formulations where the active ingredient degrades under light exposure, the opacifying capacity of the coating is not a cosmetic detail. It is part of the stability profile of the product.
Titanium dioxide also contributes to batch to batch visual consistency. Two batches coated with the same formulation should look identical on a pharmacy shelf, and an opacifier with stable particle size and refractive properties supports that consistency across production runs.
Why It Matters
The regulatory history of titanium dioxide has created uncertainty that does not match its current approval status. The European Union banned titanium dioxide as a food additive in 2022, a decision based on genotoxicity concerns raised by the European Food Safety Authority. That ban applies to food products and does not extend to pharmaceuticals, but it triggered a separate review of titanium dioxide's use in medicinal products.
That review has now concluded. In August 2025, the European Commission published a Staff Working Document confirming that titanium dioxide remains approved as a colorant in medicinal products. This followed an April 2024 review by the European Medicines Agency, which found that titanium dioxide is essential for the safety, quality and efficacy of a large share of the medicines that contain it. The Agency identified no viable alternatives across the roughly 91,000 human medicinal products and 1,600 veterinary products that currently use titanium dioxide, and estimated that reformulating that scale of the pharmaceutical portfolio would take more than 12 years once regulatory post-approval processes are accounted for.
Outside the EU, the position has remained stable. In the United States, titanium dioxide continues to be authorised as a color additive exempt from certification, and no other major regulatory jurisdiction has followed the EU's food additive ban as it applies to pharmaceuticals.
For a buyer, the practical takeaway is that titanium dioxide is not currently a compliance risk in the way that nitrosamines or certain solvent residues are. It is, however, a topic that procurement and regulatory teams should expect to be asked about, by auditors, by customers in markets sensitive to the food additive ban and by internal stakeholders who have seen the headlines without the regulatory context behind them.
The Regulatory Position in Detail
Two separate regulatory tracks need to be kept distinct.
The food additive track. Titanium dioxide, designated E171, was withdrawn as an authorised food additive in the European Union under Commission Regulation (EU) 2022/63, effective from August 2022. This decision applied to food and dietary supplements and was driven by genotoxicity concerns identified in an EFSA safety assessment.
The pharmaceutical excipient track. The European Commission separately asked the European Medicines Agency to assess what removing titanium dioxide from medicinal products would mean. The EMA's review concluded in 2024, and the Commission's August 2025 Staff Working Document confirmed that titanium dioxide remains permitted under Regulation (EU) 2022/63 for use in medicines, on the basis that no viable alternative currently meets the functional and safety requirements across the full range of affected products.
These two tracks have run on different timelines and reached different conclusions, and a buyer who only saw coverage of the food additive ban may not be aware that the pharmaceutical question has since been resolved in favour of continued use, at least for the present regulatory cycle.
Alternatives to TiO2 and Their Trade-Offs
Even with titanium dioxide's continued approval, some formulators are exploring alternatives, whether for specific markets with heightened sensitivity, for new product development where a titanium dioxide free claim has commercial value, or simply to build familiarity with substitutes ahead of any future regulatory change.
Calcium carbonate is the most commonly cited alternative and is the only other white drug colorant currently approved in the EU. Particle engineered grades of calcium carbonate can achieve opacity and process efficiency that approach titanium dioxide performance, with tablet properties such as friability and hardness reported as comparable in coated tablets.
The trade-offs are real. Achieving opacity close to titanium dioxide typically requires a thicker coating, which means a higher coating weight gain and a longer process time. Even with a thicker film, the resulting opacity has in some studies been insufficient to protect photolabile active ingredients to the same degree as titanium dioxide. Calcium carbonate also has buffering properties and can shift the local pH of the dosage form, which raises compatibility considerations for acidic active ingredients such as salicylic acid or certain antibiotics.
Other inorganic opacifiers including magnesium carbonate, calcium sulfate, talc and aluminium silicates have also been studied, but none has been identified as a complete substitute that addresses both the functional performance and the long term regulatory profile that titanium dioxide currently offers.
The practical conclusion is that alternatives exist and can work for specific formulations, but none currently functions as a direct drop-in replacement across the full range of dosage forms and active ingredients where titanium dioxide is used today.
How This Affects Coating System Selection
For a formulator working with DRCOAT® ready-to-use coating systems or building a custom formulation with DRUGCOAT® polymers, titanium dioxide content is one specification among several, and it should be evaluated alongside the rest of the formulation rather than in isolation.
If the active ingredient is photolabile, the opacifying performance of the coating system needs to meet the stability requirements demonstrated in development, and any change to the opacifier should be evaluated against the same photostability data that supported the original formulation.
If the formulation includes a titanium dioxide free coating system, the buyer should ask what opacifier is used in its place, what coating weight gain is required to achieve the target appearance, and whether any compatibility studies have been completed for the specific active ingredient.
If the current formulation uses titanium dioxide and there is no regulatory or commercial driver to change it, the most defensible position is often to continue with the current formulation while staying informed about the regulatory position, rather than undertaking a reformulation in response to a ban that does not currently apply to the product.
Applications by Dosage Form
Common Challenges
Conflating the food additive ban with pharmaceutical status. This is the most common source of confusion among buyers, and it leads to questions and sometimes reformulation decisions based on a ban that does not apply to the product in question.
Underestimating the coating weight gain impact of alternatives. A formulator who switches to an alternative opacifier without adjusting the coating process parameters may find the target appearance is not achieved at the original coating weight, requiring rework.
Assuming all titanium dioxide free systems are equivalent. Different alternative opacifiers carry different compatibility profiles, particularly around pH sensitive active ingredients, and a titanium dioxide free claim does not by itself indicate which alternative is used or whether it has been validated for a specific formulation.
Treating the regulatory position as permanent. The current approval reflects the present regulatory cycle. Buyers in regulated markets should keep a watching brief on this topic without acting prematurely on it.
Formulation Insights
The titanium dioxide conversation illustrates a broader point about excipient selection. A regulatory question that dominates industry discussion for several years can resolve in favour of the status quo, and a formulation strategy built around an anticipated ban that does not materialise carries its own costs in reformulation effort and validation work.
At the same time, having a titanium dioxide free option available, validated and ready, costs little relative to the disruption of needing one quickly if the regulatory position does change in a future review cycle. Our approach is to support both paths: continued supply of titanium dioxide containing DRCOAT® and DRUGCOAT® systems for formulations where no change is needed, and titanium dioxide free formulations for buyers who want that option in place now.
FAQ
1. Is titanium dioxide banned in pharmaceutical products?
No. Titanium dioxide is banned as a food additive in the European Union since 2022, but this does not apply to pharmaceuticals. The European Commission confirmed in August 2025 that titanium dioxide remains approved for use in medicinal products.
2. Why was titanium dioxide reviewed for pharmaceutical use if the food ban does not apply?
The European Commission asked the European Medicines Agency to assess the question separately, given the genotoxicity concerns that drove the food additive ban. The Agency's review concluded that titanium dioxide is essential and that no viable alternative currently exists across the full range of affected medicines.
3. What is the main alternative to titanium dioxide in coatings?
Calcium carbonate, particularly particle engineered grades, is the most studied alternative and the only other white drug colorant approved in the EU. It typically requires a thicker coating to approach the opacity of titanium dioxide.
4. Should we reformulate away from titanium dioxide now?
Not on the basis of current regulation, unless a specific market or customer requirement drives it. The pharmaceutical approval was reaffirmed in 2025. A titanium dioxide free option can still be developed in parallel as a contingency.
5. Do DRCOAT® and DRUGCOAT® systems support titanium dioxide free formulations?
Yes. Both ranges can be formulated with or without titanium dioxide depending on the requirements of the dosage form and the active ingredient.
Conclusion
The titanium dioxide question has moved from an open regulatory uncertainty to a resolved position, at least for the current cycle, and buyers who continue to treat it as an unresolved risk are working from outdated information. The more useful question for a formulation team is not whether titanium dioxide will be banned, but whether the current coating system, with or without titanium dioxide, meets the opacity and stability requirements of the specific product.
Our DRCOAT® and DRUGCOAT® ranges are formulated to support both titanium dioxide containing and titanium dioxide free systems, backed by EXCiPACT GMP certification, US DMF registration and WHO cGMP compliance across the range.
Evaluating TiO2 in Your Coating System? Talk to Us.
Tell us whether your current formulation uses titanium dioxide and what your regulatory or commercial drivers are for considering a change. We will share the formulation options and stability considerations relevant to your dosage form.
Write to us at contact@vikramthermo.com
.jpg)
- Venue:
- Date:
- Booth:
- Time:
- Hosted by:
- Venue:
- Date:
- Booth:
- Time:
- Hosted by:
